Univariate and multivariate stepwise Cox regression for baseline CYR61 in TT3ab (OS)
| . | Variable . | n/N (%) . | HR (95% CI) . | P value . |
|---|---|---|---|---|
| Univariate | GEP MY subgroup | 28/264 (11%) | 1.04 (0.50-2.18) | .912 |
| Focal lesions at BS by MRI >0 | 184/264 (70%) | 1.04 (0.63-1.74) | .868 | |
| GEP LB subgroup | 34/264 (13%) | 0.93 (0.46-1.87) | .829 | |
| GEP CD-2 subgroup | 38/264 (14%) | 0.75 (0.36-1.57) | .446 | |
| GEP HY subgroup | 70/264 (27%) | 0.80 (0.46-1.41) | .446 | |
| CYR61 210764_s_at expression at BS | N = 264 | 0.92 (0.76-1.12) | .429 | |
| GEP CD-1 subgroup | 15/264 (6%) | 0.47 (0.12-1.92) | .294 | |
| CRP ≥8 mg/L | 77/264 (29%) | 1.43 (0.87-2.33) | .155 | |
| CYR61 201289_at expression at BS | N = 264 | 0.88 (0.75-1.03) | .101 | |
| GEP MS subgroup | 40/264 (15%) | 0.48 (0.21-1.11) | .087 | |
| Focal lesions at BS by PET >0 | 177/264 (67%) | 1.63 (0.94-2.82) | .079 | |
| Age ≥65 y | 71/264 (27%) | 1.56 (0.95-2.56) | .077 | |
| CYR61 210764_s_at at BS high in tt3ab (OS) | 35/264 (13%) | 0.37 (0.13-1.01) | .052 | |
| CYR61 201289_at at BS high in tt3ab (OS) | 90/264 (34%) | 0.58 (0.33-1.00) | .048 | |
| GEP MF subgroup | 21/264 (8%) | 2.35 (1.23-4.48) | .009 | |
| Hemoglobin <10 g/dL | 88/264 (33%) | 1.94 (1.21-3.10) | .006 | |
| GEP TP53 deletion | 32/264 (12%) | 2.27 (1.26-4.09) | .006 | |
| Creatinine ≥2.0 mg/dL | 17/264 (6%) | 2.65 (1.35-5.17) | .004 | |
| Albuminin <3.5 g/dL | 77/264 (29%) | 2.53 (1.57-4.07) | <.001 | |
| B2M ≥3.5 mg/L | 134/264 (51%) | 2.60 (1.56-4.31) | <.001 | |
| B2M >5.5 mg/L | 66/264 (25%) | 3.29 (2.05-5.29) | <.001 | |
| LDH ≥190 U/L | 64/264 (24%) | 2.76 (1.71-4.44) | <.001 | |
| Baseline 70-gene high risk | 40/264 (15%) | 5.07 (3.09-8.32) | <.001 | |
| Cytogenetic abnormalities | 90/264 (34%) | 3.31 (2.06-5.32) | <.001 | |
| GEP PR subgroup | 26/264 (10%) | 3.29 (1.83-5.93) | <.001 | |
| Proliferation index >10 | 27/264 (10%) | 4.72 (2.77-8.03) | <.001 | |
| Multivariate | GEP MF subgroup | 21/264 (8%) | 2.20 (1.11-4.38) | .024 |
| B2M > 5.5 mg/L | 66/264 (25%) | 1.92 (1.14-3.24) | .015 | |
| LDH ≥ 190 U/L | 64/264 (24%) | 1.94 (1.15-3.25) | .012 | |
| Albuminin < 3.5 g/dL | 77/264 (29%) | 1.93 (1.17-3.19) | .011 | |
| Age ≥65 y | 71/264 (27%) | 2.01 (1.19-3.38) | .009 | |
| CYR61 201289_at expression at BS | N = 264 | 0.78 (0.66-0.93) | .006 | |
| Cytogenetic abnormalities | 90/264 (34%) | 2.39 (1.47-3.89) | <.001 | |
| Proliferation index >10 | 27/264 (10%) | 3.83 (2.17-6.77) | <.001 |
| . | Variable . | n/N (%) . | HR (95% CI) . | P value . |
|---|---|---|---|---|
| Univariate | GEP MY subgroup | 28/264 (11%) | 1.04 (0.50-2.18) | .912 |
| Focal lesions at BS by MRI >0 | 184/264 (70%) | 1.04 (0.63-1.74) | .868 | |
| GEP LB subgroup | 34/264 (13%) | 0.93 (0.46-1.87) | .829 | |
| GEP CD-2 subgroup | 38/264 (14%) | 0.75 (0.36-1.57) | .446 | |
| GEP HY subgroup | 70/264 (27%) | 0.80 (0.46-1.41) | .446 | |
| CYR61 210764_s_at expression at BS | N = 264 | 0.92 (0.76-1.12) | .429 | |
| GEP CD-1 subgroup | 15/264 (6%) | 0.47 (0.12-1.92) | .294 | |
| CRP ≥8 mg/L | 77/264 (29%) | 1.43 (0.87-2.33) | .155 | |
| CYR61 201289_at expression at BS | N = 264 | 0.88 (0.75-1.03) | .101 | |
| GEP MS subgroup | 40/264 (15%) | 0.48 (0.21-1.11) | .087 | |
| Focal lesions at BS by PET >0 | 177/264 (67%) | 1.63 (0.94-2.82) | .079 | |
| Age ≥65 y | 71/264 (27%) | 1.56 (0.95-2.56) | .077 | |
| CYR61 210764_s_at at BS high in tt3ab (OS) | 35/264 (13%) | 0.37 (0.13-1.01) | .052 | |
| CYR61 201289_at at BS high in tt3ab (OS) | 90/264 (34%) | 0.58 (0.33-1.00) | .048 | |
| GEP MF subgroup | 21/264 (8%) | 2.35 (1.23-4.48) | .009 | |
| Hemoglobin <10 g/dL | 88/264 (33%) | 1.94 (1.21-3.10) | .006 | |
| GEP TP53 deletion | 32/264 (12%) | 2.27 (1.26-4.09) | .006 | |
| Creatinine ≥2.0 mg/dL | 17/264 (6%) | 2.65 (1.35-5.17) | .004 | |
| Albuminin <3.5 g/dL | 77/264 (29%) | 2.53 (1.57-4.07) | <.001 | |
| B2M ≥3.5 mg/L | 134/264 (51%) | 2.60 (1.56-4.31) | <.001 | |
| B2M >5.5 mg/L | 66/264 (25%) | 3.29 (2.05-5.29) | <.001 | |
| LDH ≥190 U/L | 64/264 (24%) | 2.76 (1.71-4.44) | <.001 | |
| Baseline 70-gene high risk | 40/264 (15%) | 5.07 (3.09-8.32) | <.001 | |
| Cytogenetic abnormalities | 90/264 (34%) | 3.31 (2.06-5.32) | <.001 | |
| GEP PR subgroup | 26/264 (10%) | 3.29 (1.83-5.93) | <.001 | |
| Proliferation index >10 | 27/264 (10%) | 4.72 (2.77-8.03) | <.001 | |
| Multivariate | GEP MF subgroup | 21/264 (8%) | 2.20 (1.11-4.38) | .024 |
| B2M > 5.5 mg/L | 66/264 (25%) | 1.92 (1.14-3.24) | .015 | |
| LDH ≥ 190 U/L | 64/264 (24%) | 1.94 (1.15-3.25) | .012 | |
| Albuminin < 3.5 g/dL | 77/264 (29%) | 1.93 (1.17-3.19) | .011 | |
| Age ≥65 y | 71/264 (27%) | 2.01 (1.19-3.38) | .009 | |
| CYR61 201289_at expression at BS | N = 264 | 0.78 (0.66-0.93) | .006 | |
| Cytogenetic abnormalities | 90/264 (34%) | 2.39 (1.47-3.89) | <.001 | |
| Proliferation index >10 | 27/264 (10%) | 3.83 (2.17-6.77) | <.001 |
CI, confidence interval; P value from Wald χ-square test in Cox regression; MRI, magnetic resonance imaging; OS, overall survival; PET, positron emission tomography.
All univariate P values reported regardless of significance.
Multivariate model uses stepwise selection with entry level 0.1 and variable remains if meets the 0.05 level.